Botulinum toxin: Clinical use

Parkinsonism and Related Disorders

Volumn 12, Issue 6, 2006, Pages 331-355

  Truong, Daniel D ^a   Jost, Wolfgang H ^b  

^a Parkinson's and Movement Disorder Institute   (United States)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

Achalasia; Anal fissure; Blepharospasm; Botulinum toxin; Cervical dystonia; Cosmetic; Detrusor sphincter dyssynergia; Dystonia; Headache; Hyperhydrosis; Hyperreflexive bladder; Levator ani syndrome; Oromandibular dystonia; Pain; Parkinson's disease; Spasmodic dysphonia; Spasticity; Tourette's syndrome; Urethrism; Writer's cramp

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PHENOL; TRIHEXYPHENIDYL;

ANUS FISSURE; APPLICATION SITE ERYTHEMA; BLADDER DISEASE; BLADDER SPHINCTER PROSTHESIS; BLEPHAROSPASM; BRUXISM; CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DIPLOPIA; DRUG INDUCED DISEASE; DRY EYE; DYSPHAGIA; DYSPHONIA; DYSTONIA; ECCHYMOSIS; ESOPHAGUS ACHALASIA; EYELID EDEMA; FACE MUSCLE; FOOT DYSTONIA; GASTROINTESTINAL DISEASE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERREFLEXIA; HYPERSALIVATION; INFECTION; INJECTION SITE PAIN; LACRIMATION DISORDER; LAGOPHTHALMOS; MICTURITION DISORDER; MIGRAINE; MOUTH DROP; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NECK MUSCLE; NEUROLOGIC DISEASE; OROMANDIBULAR DYSTONIA; PAIN; PARALYSIS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PTOSIS; REVIEW; RHINITIS; SIDE EFFECT; SPASMODIC DYSPHONIA; SPASMODIC TORTICOLLIS; SPASTICITY; STRABISMUS; TARDIVE DYSKINESIA; TREMOR; UNSPECIFIED SIDE EFFECT; URETHRISM; VAGINISM; VOICE CHANGE; WRINKLE; WRITER CRAMP; XEROSTOMIA;

ANIMALS; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; EYE DISEASES; FEMALE; GASTROINTESTINAL DISEASES; GENITAL DISEASES, FEMALE; HUMANS; LARYNGEAL DISEASES; MOVEMENT DISORDERS; NERVOUS SYSTEM DISEASES; PAIN; PARKINSON DISEASE; SKIN DISEASES; UROLOGIC DISEASES;

EID: 33746901225     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.06.002     Document Type: Review

References (347)

1. Cherington M. Botulism: update and review. Semin Neurol 24 2 (2004) 155-163
2. Bakheit A.M., Ward C.D., and McLellan D.L. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 62 2 (1997) 198
3. Tugnoli V., Eleopra R., Quatrale R., Capone J.G., Sensi M., and Gastaldo E. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. Br J Dermatol 147 4 (2002) 808-809
4. Girlanda P., Vita G., Nicolosi C., Milone S., and Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55 9 (1992) 844-845
5. Scott A.B. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79 (1981) 734-770
6. Odergren T., Hjaltason H., Kaakkola S., Solders G., Hanko J., Fehling C., et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64 1 (1998) 6-12
7. Rosales R., Bigalke H., and Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 13 Suppl 1 (2006) 2-10
8. Ranoux D., Gury C., Fondarai J., Mas J.L., and Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72 4 (2002) 459-462
9. Sampaio C., Ferreira J.J., Simoes F., Rosas M.J., Magalhaes M., Correia A.P., et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov Disord 12 6 (1997) 1013-1018
10. Jost W.H., Kohl A., Brinkmann S., and Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 112 7 (2005) 905-913
11. Brashear A., Lew M.F., Dykstra D.D., Comella C.L., Factor S.A., Rodnitzky R.L., et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53 7 (1999) 1439-1446
12. Brin M.F., Lew M.F., Adler C.H., Comella C.L., Factor S.A., Jankovic J., et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53 7 (1999) 1431-1438
13. Dressler D., Adib Saberi F., and Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249 12 (2002) 1729-1732
14. Chan J., Brin M.F., and Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6 2 (1991) 119-126
15. Kessler K.R., Skutta M., and Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246 4 (1999) 265-274
16. Tsui J.K., Eisen A., Mak E., Carruthers J., Scott A., and Calne D.B. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12 4 (1985) 314-316
17. Tsui J.K., Eisen A., Stoessl A.J., Calne S., and Calne D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2 8501 (1986) 245-247
18. Stell R., Coleman R., Thompson P., and Marsden C.D. Botulinum toxin treatment of spasmodic torticollis. BMJ 297 6648 (1988) 616
19. Greene P., Kang U., Fahn S., Brin M., Moskowitz C., and Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40 8 (1990) 1213-1218
20. Brans J.W., Lindeboom R., Snoek J.W., Zwarts M.J., van Weerden T.W., Brunt E.R., et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46 4 (1996) 1066-1072
21. Lew M.F., Adornato B.T., Duane D.D., Dykstra D.D., Factor S.A., Massey J.M., et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49 3 (1997) 701-707
22. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 64 1 (1998) 13-17
23. Truong D., Duane D.D., Jankovic J., Singer C., Seeberger L.C., Comella C.L., et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20 7 (2005) 783-791
24. Pappert E., Leong M., and Royal M. Botulinum toxin type B compared with type A in the treatment of toxin-naïve patients with cervical dystonia: results from a randomized, double-blind non-inferiority study. Neurology 66 Suppl (2006) A252
25. Benecke R., Jost W.H., Kanovsky P., Ruzicka E., Comes G., and Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64 11 (2005) 1949-1951
26. Comella C.L., Jankovic J., Shannon K.M., Tsui J., Swenson M., Leurgans S., et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65 9 (2005) 1423-1429
27. Comella C.L., and Thompson P.D. Treatment of cervical dystonia with botulinum toxins. Eur J Neurol 13 Suppl 1 (2006) 16-20
28. Jankovic J., and Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 40 2 (1990) 277-280
29. Wissel J., and Poewe W. Dystonia-a clinical, neuropathological and therapeutic review. J Neural Transm Suppl 38 (1992) 91-104
30. Naumann M., Yakovleff A., and Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249 1 (2002) 57-63
31. Anderson T.J., Rivest J., Stell R., Steiger M.J., Cohen H., Thompson P.D., et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 85 9 (1992) 524-529
32. Jankovic J., Schwartz K., and Donovan D.T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 53 8 (1990) 633-639
33. Jankovic J., and Schwartz K.S. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 43 4 (1993) 834-836
34. Hsiung G.Y., Das S.K., Ranawaya R., Lafontaine A.L., and Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17 6 (2002) 1288-1293
35. Hallett M., and Daroff R.B. Blepharospasm: report of a workshop. Neurology 46 5 (1996) 1213-1218
36. Scott A.B., Kennedy R.A., and Stubbs H.A. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 103 3 (1985) 347-350
37. Jankovic J., and Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37 4 (1987) 616-623
38. Arthurs B., Flanders M., Codere F., Gauthier S., Dresner S., and Stone L. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can J Ophthalmol 22 1 (1987) 24-28
39. Elston J.S. Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections. Br J Ophthalmol 71 9 (1987) 664-668
40. Truong D. Randomized controlled trial of botulinum type A toxin complex (Dysport) for the treatment of benign essential blepharospasm. In: World congress of neurology, Sydney, 2005, p. 903.
41. Nussgens Z., and Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235 4 (1997) 197-199
42. Jost W.H., and Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248 Suppl 1 (2001) 21-24
43. MacAndie K., and Kemp E. Impact on quality of life of botulinum toxin treatments for essential blepharospasm. Orbit 23 4 (2004) 207-210
44. Reimer J., Gilg K., Karow A., Esser J., and Franke G.H. Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 111 1 (2005) 64-70
45. Tucha O., Naumann M., Berg D., Alders G.L., and Lange K.W. Quality of life in patients with blepharospasm. Acta Neurol Scand 103 1 (2001) 49-52
46. Roggenkamper P., Jost W.H., Bihari K., Comes G., and Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113 (2006) 303-312
47. Dutton J.J., and Buckley E.G. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 95 11 (1988) 1529-1534
48. Price J., and O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust NZ J Ophthalmol 22 4 (1994) 255-260
49. Price J., and O'Day J. A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin. J Clin Neuroophthalmol 13 1 (1993) 67-71
50. Taylor J.D., Kraft S.P., Kazdan M.S., Flanders M., Cadera W., and Orton R.B. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 26 3 (1991) 133-138
51. Grandas F., Elston J., Quinn N., and Marsden C.D. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51 6 (1988) 767-772
52. Mezaki T., Kaji R., Brin M.F., Hirota-Katayama M., Kubori T., Shimizu T., et al. Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial. Mov Disord 14 6 (1999) 1017-1020
53. Zappia J.J., Wiet R.J., Chouhan A., and Zhao J.C. Pitfalls in the diagnosis of hemifacial spasm. Laryngoscope 107 4 (1997) 461-465
54. Yoshimura D.M., Aminoff M.J., Tami T.A., and Scott A.B. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 15 9 (1992) 1045-1049
55. Park Y.C., Lim J.K., Lee D.K., and Yi S.D. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 8 5 (1993) 334-340
56. Brin M.F., Fahn S., Moskowitz C., Friedman A., Shale H.M., Greene P.E., et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2 4 (1987) 237-254
57. Tan E.K., Fook-Chong S., Lum S.Y., and Lim E. Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). J Neurol Sci 219 1-2 (2004) 151-155
58. Elston J.S. Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 49 7 (1986) 827-829
59. Elston J.S. Botulinum toxin A in clinical medicine. J Physiol (Paris) 84 4 (1990) 285-289
60. Jitpimolmard S., Tiamkao S., and Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 64 6 (1998) 751-757
61. Cakmur R., Ozturk V., Uzunel F., Donmez B., and Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 249 1 (2002) 64-68
62. Armstrong M.W., Mountain R.E., and Murray J.A. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol Allied Sci 21 1 (1996) 15-20
63. Bhattacharyya N., and Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg 127 4 (2001) 389-392
64. Blitzer A., Brin M.F., Greene P.E., and Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 98 2 (1989) 93-97
65. Hermanowicz N., and Truong D.D. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 101 11 (1991) 1216-1218
66. Tan E.K., and Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53 9 (1999) 2102-2107
67. Bhidayasiri R., Cardoso F., and Truong D.D. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 13 Suppl 1 (2006) 21-29
68. Behari M., Singh K.K., Seshadri S., Prasad K., and Ahuja G.K. Botulinum toxin A in blepharospasm and hemifacial spasm. J Assoc Physicians India 42 3 (1994) 205-208
69. Berardelli A., Formica A., Mercuri B., Abbruzzese G., Agnoli A., Agostino R., et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Ital J Neurol Sci 14 5 (1993) 361-367
70. Laskawi R., and Rohrbach S. Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin. Laryngorhinootologie 80 12 (2001) 708-713
71. Maurri S., Brogelli S., Alfieri G., and Barontini F. Use of botulinum toxin in Meige's disease. Riv Neurol 58 6 (1988) 245-248
72. Poungvarin N., Devahastin V., Chaisevikul R., Prayoonwiwat N., and Viriyavejakul A. Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients. J Med Assoc Thai 80 1 (1997) 1-8
73. Van den Bergh P., Francart J., Mourin S., Kollmann P., and Laterre E.C. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 18 7 (1995) 720-729
74. Brin M. Oromandibular dystonia: treatment of 96 patients with botulinum toxin type A. In: Jankovic J., and Hallett M. (Eds). Therapy with botulinum toxin (1994), Marcel Dekker, New York 429-435
75. Wan X.H., Vuong K.D., and Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J 20 1 (2005) 44-47
76. Ramazzini B. Diseases of workers translated from De Morbis Artificum Diatriba of 1713 (1964), Haffner, New York
77. Altschuler E.L. Ramazzini and writer's cramp. Lancet 365 9463 (2005) 938
78. Solly S. Clinical lectures on scriveners' palsy, or the paralysis of writers. 1864. Clin Orthop Relat Res 351 (1998) 4-9
79. Karp B.I., Cole R.A., Cohen L.G., Grill S., Lou J.S., and Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 44 1 (1994) 70-76
80. Karp B.I. Botulinum toxin treatment of occupational and focal hand dystonia. Mov Disord 19 Suppl 8 (2004) S116-S119
81. Cohen L.G., Hallett M., Geller B.D., and Hochberg F. Treatment of focal dystonias of the hand with botulinum toxin injections. J Neurol Neurosurg Psychiatry 52 3 (1989) 355-363
82. Lees A.J., Turjanski N., Rivest J., Whurr R., Lorch M., and Brookes G. Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin. J Neurol 239 1 (1992) 1-4
83. Poungvarin N. Writer's cramp: the experience with botulinum toxin injections in 25 patients. J Med Assoc Thai 74 5 (1991) 239-247
84. Turjanski N., Pirtosek Z., Quirk J., Anderson T.J., Rivest J., Marsden C.D., et al. Botulinum toxin in the treatment of writer's cramp. Clin Neuropharmacol 19 4 (1996) 314-320
85. Wissel J., Kabus C., Wenzel R., Klepsch S., Schwarz U., Nebe A., et al. Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry 61 2 (1996) 172-175
86. Djebbari R., du Montcel S.T., Sangla S., Vidal J.S., Gallouedec G., and Vidailhet M. Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin. J Neurol Neurosurg Psychiatry 75 12 (2004) 1688-1691
87. Tsui J.K., Bhatt M., Calne S., and Calne D.B. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology 43 1 (1993) 183-185
88. Das C.P., Dressler D., and Hallett M. Botulinum toxin therapy of writer's cramp. Eur J Neurol 13 Suppl 1 (2006) 55-59
89. Behari M. Botulinum toxin in the treatment of writer's cramp. J Assoc Physicians India 47 7 (1999) 694-698
90. Schuele S., Jabusch H.C., Lederman R.J., and Altenmuller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology 64 2 (2005) 341-343
91. Schuele S., and Lederman R.J. Long-term outcome of focal dystonia in string instrumentalists. Mov Disord 19 1 (2004) 43-48
92. Duarte J., Sempere A.P., Coria F., Claveria L.E., Frech F.A., Mataix A.L., et al. Isolated idiopathic adult-onset foot dystonia and treatment with botulinum toxin. J Neurol 242 2 (1995) 114-115
93. Singer C., and Papapetropoulos S. Adult-onset primary focal foot dystonia. Parkinsonism Relat Disord 12 1 (2006) 57-60
94. Pacchetti C., Albani G., Martignoni E., Godi L., Alfonsi E., and Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 10 3 (1995) 333-336
95. Quirk J.A., Sheean G.L., Marsden C.D., and Lees A.J. Treatment of nonoccupational limb and trunk dystonia with botulinum toxin. Mov Disord 11 4 (1996) 377-383
96. Ghika J., Nater B., Henderson J., Bogousslavsky J., and Regli F. Delayed segmental axial dystonia of the trunk on standing after lumbar disk operation. J Neurol Sci 152 2 (1997) 193-197
97. Mezaki T., Kaji R., Hamano T., Nagamine T., Shibasaki H., Shimizu T., et al. Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J Neurol Neurosurg Psychiatry 57 12 (1994) 1535-1537
98. Comella C.L., Shannon K.M., and Jaglin J. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord 13 3 (1998) 552-555
99. Fahn S. Tardive dyskinesias (1984), Churchill Livingstone, Edinburgh
100. Burke R.E., Fahn S., Jankovic J., Marsden C.D., Lang A.E., Gollomp S., et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32 12 (1982) 1335-1346
101. Kang U.J., Burke R.E., and Fahn S. Tardive dystonia. Adv Neurol 50 (1988) 415-429
102. Truong D.D., Hermanowicz N., and Rontal M. Botulinum toxin in treatment of tardive dyskinetic syndrome. J Clin Psychopharmacol 10 6 (1990) 438-439
103. Jankovic J., Leder S., Warner D., and Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 41 7 (1991) 1088-1091
104. Stip E., Faughnan M., Desjardin I., and Labrecque R. Botulinum toxin in a case of severe tardive dyskinesia mixed with dystonia. Br J Psychiatry 161 (1992) 867-868
105. Kaufman D.M. Use of botulinum toxin injections for spasmodic torticollis of tardive dystonia. J Neuropsychiatry Clin Neurosci 6 1 (1994) 50-53
106. Yasufuku-Takano J., Sakurai M., Kanazawa I., and Nagaoka M. Successful treatment of intractable tardive dyskinesia with botulinum toxin. J Neurol Neurosurg Psychiatry 58 4 (1995) 511-512
107. Shulman L.M., Singer C., and Weiner W.J. Improvement of both tardive dystonia and akathisia after botulinum toxin injection. Neurology 46 3 (1996) 844-845
108. Tarsy D., Kaufman D., Sethi K.D., Rivner M.H., Molho E., and Factor S. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 20 1 (1997) 90-93
109. Kanovsky P., Streitova H., Bares M., and Hortova H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect. Mov Disord 14 5 (1999) 886-888
110. Feve A., Angelard B., and Lacau St Guily J. Laryngeal tardive dyskinesia. J Neurol 242 7 (1995) 455-459
111. Scott B.L., Jankovic J., and Donovan D.T. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 11 4 (1996) 431-433
112. Trimble M.R., Whurr R., Brookes G., and Robertson M.M. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 13 3 (1998) 617-619
113. Salloway S., Stewart C.F., Israeli L., Morales X., Rasmussen S., Blitzer A., et al. Botulinum toxin for refractory vocal tics. Mov Disord 11 6 (1996) 746-748
114. Krauss J.K., and Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord 11 5 (1996) 563-566
115. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 9 3 (1994) 347-349
116. Kwak C.H., Hanna P.A., and Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 57 8 (2000) 1190-1193
117. Porta M., Maggioni G., Ottaviani F., and Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci 24 6 (2004) 420-423
118. Marras C., Andrews D., Sime E., and Lang A.E. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 56 5 (2001) 605-610
119. Pal P.K., Samii A., Schulzer M., Mak E., and Tsui J.K. Head tremor in cervical dystonia. Can J Neurol Sci 27 2 (2000) 137-142
120. Wissel J., Masuhr F., Schelosky L., Ebersbach G., and Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 12 5 (1997) 722-726
121. Jankovic J., and Schwartz K. Botulinum toxin treatment of tremors. Neurology 41 8 (1991) 1185-1188
122. Henderson J.M., Ghika J.A., Van Melle G., Haller E., and Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol 36 1 (1996) 29-35
123. Jankovic J., Schwartz K., Clemence W., Aswad A., and Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 11 3 (1996) 250-256
124. Trosch R.M., and Pullman S.L. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord 9 6 (1994) 601-609
125. Brin M.F., Lyons K.E., Doucette J., Adler C.H., Caviness J.N., Comella C.L., et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 56 11 (2001) 1523-1528
126. Deuschl G., Lohle E., Heinen F., and Lucking C. Ear click in palatal tremor: its origin and treatment with botulinum toxin. Neurology 41 10 (1991) 1677-1679
127. Jamieson D.R., Mann C., O'Reilly B., and Thomas A.M. Ear clicks in palatal tremor caused by activity of the levator veli palatini. Neurology 46 4 (1996) 1168-1169
128. Grazko M.A., Polo K.B., and Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45 4 (1995) 712-717
129. Baker R., Jasinski M., Maciag-Tymecka I., Michalowska-Mrozek J., Bonikowski M., Carr L., et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 44 10 (2002) 666-675
130. Brashear A., Gordon M.F., Elovic E., Kassicieh V.D., Marciniak C., Do M., et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347 6 (2002) 395-400
131. Bakheit A.M., Thilmann A.F., Ward A.B., Poewe W., Wissel J., Muller J., et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31 10 (2000) 2402-2406
132. Bakheit A.M., Pittock S., Moore A.P., Wurker M., Otto S., Erbguth F., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 8 6 (2001) 559-565
133. Brashear A., McAfee A.L., Kuhn E.R., and Ambrosius W.T. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 84 1 (2003) 103-107
134. Burbaud P., Wiart L., Dubos J.L., Gaujard E., Debelleix X., Joseph P.A., et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 61 3 (1996) 265-269
135. Childers M.K., Brashear A., Jozefczyk P., Reding M., Alexander D., Good D., et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 85 7 (2004) 1063-1069
136. Hyman N., Barnes M., Bhakta B., Cozens A., Bakheit M., Kreczy-Kleedorfer B., et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68 6 (2000) 707-712
137. Mall V., Heinen F., Siebel A., Bertram C., Hafkemeyer U., Wissel J., et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 48 1 (2006) 10-13
138. Mancini F., Sandrini G., Moglia A., Nappi G., and Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 26 1 (2005) 26-31
139. Simpson D.M., Alexander D.N., O'Brien C.F., Tagliati M., Aswad A.S., Leon J.M., et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46 5 (1996) 1306-1310
140. Smith S.J., Ellis E., White S., and Moore A.P. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 14 1 (2000) 5-13
141. Snow B.J., Tsui J.K., Bhatt M.H., Varelas M., Hashimoto S.A., and Calne D.B. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28 4 (1990) 512-515
142. Pittock S.J., Moore A.P., Hardiman O., Ehler E., Kovac M., Bojakowski J., et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 15 4 (2003) 289-300
143. Verplancke D., Snape S., Salisbury C.F., Jones P.W., and Ward A.B. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 19 2 (2005) 117-125
144. Houltram J., Noble I., Boyd R.N., Corry I., Flett P., and Graham H.K. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol 8 Suppl 5 (2001) 194-202
145. Ward A., Roberts G., Warner J., and Gillard S. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med 37 4 (2005) 252-257
146. Kirazli Y., On A.Y., Kismali B., and Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 77 6 (1998) 510-515
147. Brashear A., McAfee A.L., Kuhn E.R., and Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 85 5 (2004) 705-709
148. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87 10 (1980) 1044-1049
149. Magoon E.H. Botulinum toxin chemo-denervation for strabismus in infants and children. J Pediatr Ophthalmol Strabismus 21 3 (1984) 110-113
150. Scott A.B. Injection treatment of endocrine orbital myopathy. Doc Ophthalmol 58 1 (1984) 141-145
151. Quah B.L., Ling Y.L., Cheong P.Y., and Balakrishnan V. A review of 5 years' experience in the use of botulinium toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre. Singapore Med J 40 6 (1999) 405-409
152. Kikkawa D.O., Cruz Jr. R.C., Christian W.K., Rikkers S., Weinreb R.N., Levi L., et al. Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 135 4 (2003) 427-431
153. Gusek-Schneider G.C., and Erbguth F. [Protective ptosis by botulinum A toxin injection in corneal affectations]. Klin Monatsbl Augenheilkd 213 1 (1998) 15-22
154. Ellis M.F., and Daniell M. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin Exp Ophthalmol 29 6 (2001) 394-399
155. Boroojerdi B., Ferbert A., Schwarz M., Herath H., and Noth J. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry 65 1 (1998) 111-114
156. Keegan D.J., Geerling G., Lee J.P., Blake G., Collin J.R., and Plant G.T. Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol 86 1 (2002) 43-46
157. Montoya F.J., Riddell C.E., Caesar R., and Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye 16 6 (2002) 705-709
158. Riemann R., Pfennigsdorf S., Riemann E., and Naumann M. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report. Ophthalmology 106 12 (1999) 2322-2324
159. Hofmann R.J. Treatment of Frey's syndrome (gustatory sweating) and 'crocodile tears' (gustatory epiphora) with purified botulinum toxin. Ophthalmic Plast Reconstr Surg 16 4 (2000) 289-291
160. Kyrmizakis D.E., Pangalos A., Papadakis C.E., Logothetis J., Maroudias N.J., and Helidonis E.S. The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg 62 7 (2004) 840-844
161. Blitzer A., Brin M.F., Fahn S., Lange D., and Lovelace R.E. Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 96 11 (1986) 1300-1301
162. Troung D.D., Rontal M., Rolnick M., Aronson A.E., and Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 101 6 Part 1 (1991) 630-634
163. Boutsen F., Cannito M.P., Taylor M., and Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res 45 3 (2002) 469-481
164. Watts C.C., Whurr R., and Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia. Cochrane Database Syst Rev 3 (2004) CD004327
165. Whurr R., Nye C., and Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord 33 Suppl (1998) 327-329
166. Brin M.F., Blitzer A., and Stewart C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Adv Neurol 78 (1998) 237-252
167. Blitzer A., Brin M.F., and Stewart C.F. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108 10 (1998) 1435-1441
168. Miller R.H., Woodson G.E., and Jankovic J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg 113 6 (1987) 603-605
169. Ford C.N., Bless D.M., and Lowery J.D. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg 103 5 Part 1 (1990) 752-758
170. Rhew K., Fiedler D.A., and Ludlow C.L. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg 111 6 (1994) 787-794
171. Green D.C., Berke G.S., Ward P.H., and Gerratt B.R. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol 101 11 (1992) 883-887
172. Garcia Ruiz P.J., Cenjor Espanol C., Sanchez Bernardos V., Astarloa R., Sanabria J., and Garcia de Yebenes J. Botulinum toxin treatment for spasmodic dysphonia: percutaneous versus transoral approach. Clin Neuropharmacol 21 3 (1998) 196-198
173. Ludlow C.L., Naunton R.F., Sedory S.E., Schulz G.M., and Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 38 8 (1988) 1220-1225
174. Van Zandijcke M., and Marchau M.M. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry 53 6 (1990) 530
175. Tan E.K., and Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 131 2 (2000) 211-216
176. Shaari C.M., Sanders I., Wu B.L., and Biller H.F. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 112 4 (1995) 566-571
177. Kim K.S., Kim S.S., Yoon J.H., and Han J.W. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol 112 3 (1998) 248-251
178. Rohrbach S., and Laskawi R. Minimally invasive application of botulinum toxin type A in nasal hypersecretion. ORL J Otorhinolaryngol Relat Spec 63 6 (2001) 382-384
179. Unal M., Sevim S., Dogu O., Vayisoglu Y., and Kanik A. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol 123 9 (2003) 1060-1063
180. Ellies M., Laskawi R., Rohrbach-Volland S., and Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61 4 (2003) 454-457
181. Giess R., Naumann M., Werner E., Riemann R., Beck M., Puls I., et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69 1 (2000) 121-123
182. Lagalla G., Millevolte M., Capecci M., Provinciali L., and Ceravolo M.G. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord (2006)
183. Jongerius P.H., van den Hoogen F.J., van Limbeek J., Gabreels F.J., van Hulst K., and Rotteveel J.J. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 114 3 (2004) 620-627
184. Lipp A., Trottenberg T., Schink T., Kupsch A., and Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61 9 (2003) 1279-1281
185. Racette B.A., Good L., Sagitto S., and Perlmutter J.S. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 18 9 (2003) 1059-1061
186. Ondo W.G., Hunter C., and Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62 1 (2004) 37-40
187. Dressler D., and Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49 1 (2003) 34-38
188. Bhidayasiri R., and Truong D.D. Expanding use of botulinum toxin. J Neurol Sci 235 1-2 (2005) 1-9
189. Mancini F., Zangaglia R., Cristina S., Sommaruga M.G., Martignoni E., Nappi G., et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18 6 (2003) 685-688
190. Ellies M., Rohrbach-Volland S., Arglebe C., Wilken B., Laskawi R., and Hanefeld F. Successful management of drooling with botulinum toxin A in neurologically disabled children. Neuropediatrics 33 6 (2002) 327-330
191. Suskind D.L., and Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112 1 (2002) 73-81
192. Pal P.K., Calne D.B., Calne S., and Tsui J.K. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54 1 (2000) 244-247
193. Jost W.H. Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 14 6 (1999) 1057
194. Tan E.K., Lo Y.L., Seah A., and Auchus A.P. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 190 1-2 (2001) 95-97
195. Winterholler M.G., Erbguth F.J., Wolf S., and Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 70 3 (2001) 417-418
196. Bothwell J.E., Clarke K., Dooley J.M., Gordon K.E., Anderson R., Wood E.P., et al. Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol 27 1 (2002) 18-22
197. Porta M., Gamba M., Bertacchi G., and Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 70 4 (2001) 538-540
198. Dogu O., Apaydin D., Sevim S., Talas D.U., and Aral M. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 106 2 (2004) 93-96
199. Carruthers A., and Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg 24 11 (1998) 1189-1194
200. Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., and Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 2 (2004) 223-233
201. Carruthers J.A., Lowe N.J., Menter M.A., Gibson J., Nordquist M., Mordaunt J., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 6 (2002) 840-849
202. Carruthers J.D., and Carruthers J.A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18 1 (1992) 17-21
203. Keen M., Blitzer A., Aviv J., Binder W., Prystowsky J., Smith H., et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg 94 1 (1994) 94-99
204. Lowe N.J., Lask G., Yamauchi P., and Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 47 6 (2002) 834-840
205. Baumann L., Slezinger A., Vujevich J., Halem M., Bryde J., Black L., et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial. Dermatol Surg 29 5 (2003) 508-515
206. Carruthers J.D., Lowe N.J., Menter M.A., Gibson J., and Eadie N. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112 4 (2003) 1089-1098
207. Carruthers A., Carruthers J., and Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 31 4 (2005) 414-422 [discussion 22]
208. Hankins C.L., Strimling R., and Rogers G.S. Botulinum A toxin for glabellar wrinkles. Dose and response. Dermatol Surg 24 11 (1998) 1181-1183
209. Matarasso A., Matarasso S.L., Brandt F.S., and Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 103 2 (1999) 645-652 [discussion 53-5]
210. Becker-Wegerich P.M., Rauch L., and Ruzicka T. Botulinum toxin A: successful decollete rejuvenation. Dermatol Surg 28 2 (2002) 168-171
211. Guyuron B., and Huddleston S.W. Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg 93 5 (1994) 913-918
212. Foster J.A., Barnhorst D., Papay F., Oh P.M., and Wulc A.E. The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 103 4 (1996) 618-622
213. Pribitkin E.A., Greco T.M., Goode R.L., and Keane W.M. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection. Arch Otolaryngol Head Neck Surg 123 3 (1997) 321-326
214. Blitzer A., Binder W.J., Aviv J.E., Keen M.S., and Brin M.F. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 123 4 (1997) 389-392
215. Lowe N.J., Maxwell A., and Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 35 4 (1996) 569-572
216. Carruthers A., Carruthers J., and Cohen J. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg 29 5 (2003) 461-467
217. Cheshire W.P., and Freeman R. Disorders of sweating. Semin Neurol 23 4 (2003) 399-406
218. Kreyden O.P., and Scheidegger E.P. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clin Dermatol 22 1 (2004) 40-44
219. Swartling C., Naver H., Pihl-Lundin I., Hagforsen E., and Vahlquist A. Sweat gland morphology and periglandular innervation in essential palmar hyperhidrosis before and after treatment with intradermal botulinum toxin. J Am Acad Dermatol 51 5 (2004) 739-745
220. Naumann M., and Lowe N.J. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 323 7313 (2001) 596-599
221. Naumann M.K., Hamm H., and Lowe N.J. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 147 6 (2002) 1218-1226
222. Schnider P., Binder M., Auff E., Kittler H., Berger T., and Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 136 4 (1997) 548-552
223. Naumann M., Hofmann U., Bergmann I., Hamm H., Toyka K.V., and Reiners K. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134 3 (1998) 301-304
224. Naumann M., Bergmann I., Hofmann U., Hamm H., and Reiners K. Botulinum toxin for focal hyperhidrosis: technical considerations and improvements in application. Br J Dermatol 139 6 (1998) 1123-1124
225. Odderson I.R. Axillary hyperhidrosis: treatment with botulinum toxin A. Arch Phys Med Rehabil 79 3 (1998) 350-352
226. Schnider P., Binder M., Kittler H., Birner P., Starkel D., Wolff K., et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 140 4 (1999) 677-680
227. Shelley W.B., Talanin N.Y., and Shelley E.D. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 38 2 Pt 1 (1998) 227-229
228. Naumann M., Jost W.H., and Toyka K.V. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol 56 8 (1999) 914-916
229. Glogau R.G. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox. Dermatol Surg 24 8 (1998) 817-819
230. Naver H., Swartling C., and Aquilonius S.M. Treatment of focal hyperhidrosis with botulinum toxin type A. Brief overview of methodology and 2 years' experience. Eur J Neurol 6 (1999) S117-S120
231. Naver H., Swartling C., and Aquilonius S.M. Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol 7 1 (2000) 55-62
232. Heckmann M., Breit S., Ceballos-Baumann A., Schaller M., and Plewig G. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 41 6 (1999) 987-990
233. Heckmann M., Ceballos-Baumann A.O., and Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344 7 (2001) 488-493
234. Solomon B.A., and Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 42 6 (2000) 1026-1029
235. Karamfilov T., Konrad H., Karte K., and Wollina U. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase. Arch Dermatol 136 4 (2000) 487-490
236. Swartling C., Naver H., and Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 8 3 (2001) 247-252
237. Kavanagh G.M., Oh C., and Shams K. BOTOX delivery by iontophoresis. Br J Dermatol 151 5 (2004) 1093-1095
238. Heckmann M., and Plewig G. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 141 10 (2005) 1255-1259
239. Krogstad A.L., Skymne A., Pegenius G., Elam M., and Wallin B.G. No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis. Br J Dermatol 152 2 (2005) 329-333
240. Matarasso S.L. Treatment of facial chromhidrosis with botulinum toxin type A. J Am Acad Dermatol 52 1 (2005) 89-91
241. Baumann L.S., and Halem M.L. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 139 2 (2003) 226-227
242. Baumann L.S., and Halem M.L. Botulinum toxin-B and the management of hyperhidrosis. Clin Dermatol 22 1 (2004) 60-65
243. Simonetta Moreau M., Cauhepe C., Magues J.P., and Senard J.M. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 149 5 (2003) 1041-1045
244. Drobik C., and Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol 115 3 (1995) 459-461
245. Laskawi R., Drobik C., and Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope 108 3 (1998) 381-384
246. Naumann M., Zellner M., Toyka K.V., and Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 42 6 (1997) 973-975
247. Bergmann I., Dauphin M., Naumann M., Flachenecker P., Mullges W., Koltzenburg M., et al. Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin. Muscle Nerve 21 12 (1998) 1790-1793
248. Wollina U., and Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol 16 1 (2002) 40-42
249. Swartling C., Naver H., Lindberg M., and Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol 47 5 (2002) 667-671
250. Saadia D., Voustianiouk A., Wang A.K., and Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 57 11 (2001) 2095-2099
251. Wollina U., and Karamfilov T. Botulinum toxin A for palmar hyperhidrosis. J Eur Acad Dermatol Venereol 15 6 (2001) 555-558
252. Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 43 12 (2004) 969-971
253. Naumann M., Lowe N.J., Kumar C.R., and Hamm H. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 139 6 (2003) 731-736
254. Odderson I.R. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg 28 6 (2002) 480-483
255. Wollina U., Karamfilov T., and Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 46 4 (2002) 536-540
256. Kinkelin I., Hund M., Naumann M., and Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 143 4 (2000) 824-827
257. Laccourreye O., Akl E., Gutierrez-Fonseca R., Garcia D., Brasnu D., and Bonan B. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome. Arch Otolaryngol Head Neck Surg 125 3 (1999) 283-286
258. Beerens A.J., and Snow G.B. Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg 89 1 (2002) 116-119
259. Bjerkhoel A., and Trobbe O. Frey's syndrome: treatment with botulinum toxin. J Laryngol Otol 111 9 (1997) 839-844
260. Boger A., Herath H., Rompel R., and Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol 247 11 (2000) 857-861
261. Baumann L., Slezinger A., Halem M., Vujevich J., Mallin K., Charles C., et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 31 3 (2005) 263-270
262. Birklein F., Eisenbarth G., Erbguth F., and Winterholler M. Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up. J Invest Dermatol 121 6 (2003) 1312-1316
263. Schurch B., Schmid D.M., and Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342 9 (2000) 665
264. Reitz A., Stohrer M., Kramer G., Del Popolo G., Chartier-Kastler E., Pannek J., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 4 (2004) 510-515
265. Grosse J., Kramer G., and Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 5 (2005) 653-659
266. Schurch B., de Seze M., Denys P., Chartier-Kastler E., Haab F., Everaert K., et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 1 (2005) 196-200
267. Dykstra D.D., Pryor J., and Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch Phys Med Rehabil 84 9 (2003) 1399-1400
268. Reitz A., and Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 171 2 Part 1 (2004) 804 [discussion 5]
269. Ghei M., Maraj B.H., Miller R., Nathan S., O'Sullivan C., Fowler C.J., et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 174 5 (2005) 1873-1877 [discussion 7]
270. Schulte-Baukloh H., Michael T., Sturzebecher B., and Knispel H.H. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44 1 (2003) 139-143
271. Schulte-Baukloh H., Michael T., Schobert J., Stolze T., and Knispel H.H. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59 3 (2002) 325-327 [discussion 7-8]
272. Riccabona M., Koen M., Schindler M., Goedele B., Pycha A., Lusuardi L., et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171 2 Part 1 (2004) 845-848 [discussion 8]
273. Kuo H.C. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66 1 (2005) 94-98
274. Kuo H.C. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63 5 (2004) 868-872
275. Kuo H.C. Therapeutic effects of suburothelial injection of botulinum A toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67 2 (2006) 232-236
276. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., and Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 5 (1988) 919-922
277. Petit H., Wiart L., Gaujard E., Le Breton F., Ferriere J.M., Lagueny A., et al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36 2 (1998) 91-94
278. Schurch B., Hauri D., Rodic B., Curt A., Meyer M., and Rossier A.B. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155 3 (1996) 1023-1029
279. Schurch B., Hodler J., and Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 63 4 (1997) 474-476
280. Jost W.H., and Naumann M. Botulinum toxin in neuro-urological disorders. Mov Disord 19 Suppl 8 (2004) S142-S145
281. Dykstra D.D., and Sidi A.A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71 1 (1990) 24-26
282. Kuo H.C. Prostate botulinum A toxin injection-an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65 4 (2005) 670-674
283. Maria G., Brisinda G., Civello I.M., Bentivoglio A.R., Sganga G., and Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62 2 (2003) 259-264 [discussion 64-5]
284. Brin M.F., and Vapnek J.M. Treatment of vaginismus with botulinum toxin injections. Lancet 349 9047 (1997) 252-253
285. Ghazizadeh S., and Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 104 5 Part 1 (2004) 922-925
286. Pasricha P.J., Ravich W.J., Hendrix T.R., Sostre S., Jones B., and Kalloo A.N. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 332 12 (1995) 774-778
287. Annese V., Basciani M., Perri F., Lombardi G., Frusciante V., Simone P., et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 111 6 (1996) 1418-1424
288. Muehldorfer S.M., Schneider T.H., Hochberger J., Martus P., Hahn E.G., and Ell C. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy 31 7 (1999) 517-521
289. Ghoshal U.C., Chaudhuri S., Pal B.B., Dhar K., Ray G., and Banerjee P.K. Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia. Dis Esophagus 14 3-4 (2001) 227-231
290. Miller L.S., Pullela S.V., Parkman H.P., Schiano T.D., Cassidy M.J., Cohen S., et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol 97 7 (2002) 1640-1646
291. Miller L.S., Parkman H.P., Schiano T.D., Cassidy M.J., Ter R.B., Dabezies M.A., et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 41 10 (1996) 2025-2031
292. Alberty J., Oelerich M., Ludwig K., Hartmann S., and Stoll W. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Laryngoscope 110 7 (2000) 1151-1156
293. Schneider I., Thumfart W.F., Pototschnig C., and Eckel H.E. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol 103 1 (1994) 31-35
294. Pasricha P.J., Miskovsky E.P., and Kalloo A.N. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut 35 9 (1994) 1319-1321
295. Wehrmann T., Schmitt T.H., Arndt A., Lembcke B., Caspary W.F., and Seifert H. Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. Aliment Pharmacol Ther 14 11 (2000) 1469-1477
296. Gui D., Mingrone G., Valenza V., Spada P.L., Mutignani M., Runfola M., et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther 23 5 (2006) 675-680
297. Ezzeddine D., Jit R., Katz N., Gopalswamy N., and Bhutani M.S. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 55 7 (2002) 920-923
298. Miller L.S., Szych G.A., Kantor S.B., Bromer M.Q., Knight L.C., Maurer A.H., et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 97 7 (2002) 1653-1660
299. Jost W.H. Ten years' experience with botulin toxin in anal fissure. Int J Colorectal Dis 17 5 (2002) 298-302
300. Brisinda G., Bentivoglio A.R., Maria G., and Albanese A. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord 19 Suppl 8 (2004) S146-S156
301. Gui D., Rossi S., Runfola M., and Magalini S.C. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther 18 1 (2003) 1-16
302. Joo J.S., Agachan F., Wolff B., Nogueras J.J., and Wexner S.D. Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 39 10 (1996) 1107-1111
303. Maria G., Brisinda G., Bentivoglio A.R., Cassetta E., and Albanese A. Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum 43 3 (2000) 376-380
304. Ishikawa H., Mitsui Y., Yoshitomi T., Mashimo K., Aoki S., Mukuno K., et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi 105 4 (2001) 218-222
305. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 2 (2000) 245-258
306. Sala C., Andreose J.S., Fumagalli G., and Lomo T. Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions. J Neurosci 15 1 Part 2 (1995) 520-528
307. Suzuki N., Hardebo J.E., Kahrstrom J., and Owman C. Neuropeptide Y co-exists with vasoactive intestinal polypeptide and acetylcholine in parasympathetic cerebrovascular nerves originating in the sphenopalatine, otic, and internal carotid ganglia of the rat. Neuroscience 36 2 (1990) 507-519
308. Puffer E.B., Lomneth R.B., Sarkar H.K., and Singh B.R. Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process. Biochemistry 40 31 (2001) 9374-9378
309. Bolay H., Reuter U., Dunn A.K., Huang Z., Boas D.A., and Moskowitz M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8 2 (2002) 136-142
310. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 1 (2004) 35-42 [discussion 3]
311. Williamson D.J., Hill R.G., Shepheard S.L., and Hargreaves R.J. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 133 7 (2001) 1029-1034
312. Jensen R., and Olesen J. Tension-type headache: an update on mechanisms and treatment. Curr Opin Neurol 13 3 (2000) 285-289
313. Storr M., Born P., Frimberger E., Weigert N., Rosch T., Meining A., et al. Treatment of achalasia: the short-term response to botulinum toxin injection seems to be independent of any kind of pretreatment. BMC Gastroenterol 2 (2002) 19
314. Edvinsson L., and Goadsby P.J. Neuropeptides in migraine and cluster headache. Cephalalgia 14 5 (1994) 320-327
315. Foster L., Clapp L., Erickson M., and Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56 10 (2001) 1290-1293
316. Cheshire W.P., Abashian S.W., and Mann J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59 1 (1994) 65-69
317. Lang A.M. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil 83 3 (2004) 198-202
318. Lang A.M. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 84 3 Suppl 1 (2003) S69-S73 [quiz S4-5]
319. Zwart J.A., Bovim G., Sand T., and Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache 34 8 (1994) 458-462
320. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache. Curr Rev Pain 4 1 (2000) 31-35
321. Relja M., and Telarovic S. Botulinum toxin in tension-type headache. J Neurol 251 Suppl 1 (2004) I12-I14
322. Schulte-Mattler W.J., Wieser T., and Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res 4 5 (1999) 183-186
323. Schulte-Mattler W.J., and Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 109 1-2 (2004) 110-114
324. Schmitt W.J., Slowey E., Fravi N., Weber S., and Burgunder J.M. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 41 7 (2001) 658-664
325. Rollnik J.D., Tanneberger O., Schubert M., Schneider U., and Dengler R. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 40 4 (2000) 300-305
326. Padberg M., de Bruijn S.F., de Haan R.J., and Tavy D.L. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 24 8 (2004) 675-680
327. Silberstein S., Mathew N., Saper J., and Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40 6 (2000) 445-450
328. Schulte-Mattler W.J., and Martinez-Castrillo J.C. Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations. Eur J Neurol 13 Suppl 1 (2006) 51-54
329. Evers S., Vollmer-Haase J., Schwaag S., Rahmann A., Husstedt I.W., and Frese A. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24 10 (2004) 838-843
330. Schwaag S., Vollmer-Haase J., Rahman A., Frese A., Husstedt I.-W., and Evers S. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 23 (2003) 702
331. Brin M.S., Swope D.M., O'Brian C., Abbasi S., and Pogoda J.N. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation [abstract]. Cephalalgia 20 (2000) 421-422
332. Barrientos N., and Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 4 (2003) 146-151
333. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 43 8 (2003) 853-860
334. Mathew N.T., Frishberg B.M., Gawel M., Dimitrova R., Gibson J., and Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45 4 (2005) 293-307
335. Dodick D.W., Mauskop A., Elkind A.H., DeGryse R., Brin M.F., and Silberstein S.D. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45 4 (2005) 315-324
336. Ondo W.G., Vuong K.D., and Derman H.S. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 24 1 (2004) 60-65
337. Gwynn M., English J., and Baker T. Double-blind, placebo-controlled study of Myobloc (botulinum toxin type B) for the treatment of chronic headache. Headache 43 (2003) 577
338. Bagheri H., Damase-Michel C., Lapeyre-Mestre M., Cismondo S., O'Connell D., Senard J.M., et al. A study of salivary secretion in Parkinson's disease. Clin Neuropharmacol 22 4 (1999) 213-215
339. Cadeddu F., Bentivoglio A.R., Brandara F., Marniga G., Brisinda G., and Maria G. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther 22 10 (2005) 997-1003
340. Giladi N., Gurevich T., Shabtai H., Paleacu D., and Simon E.S. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol 248 7 (2001) 572-576
341. Fernandez H.H., Lannon M.C., Trieschmann M.E., and Friedman J.H. Botulinum toxin type B for gait freezing in Parkinson's disease. Med Sci Monit 10 7 (2004) CR282-CR284
342. Wieler M., Camicioli R., Jones C.A., and Martin W.R. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 65 4 (2005) 626-628
343. Shah S.N., Hornyak J., and Urquhart A.G. Flexion contracture after total knee arthroplasty in a patient with Parkinson's disease: successful treatment with botulinum toxin type A. J Arthroplasty 20 8 (2005) 1078-1080
344. Singer C., and Papapetropoulos S. Lower limb post-immobilization dystonia in Parkinson's disease. J Neurol Sci 239 1 (2005) 111-114
345. Guo Y., and Shin K. Unique use of botulinum toxin to decrease adductor tone and allow surgical excision of vulvar carcinoma. Int J Gynecol Cancer 14 1 (2004) 100-103
346. Cordivari C., Misra V.P., Catania S., and Lees A.J. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 16 5 (2001) 907-913
347. Azher S.N., and Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 65 3 (2005) 355-359